Despite concerns about the efficacy and safety of checkpoint inhibitors, many biotech companies are advancing them in clinical trials to treat cancer. By 2032, the market for these drugs could reach nearly $189.4 billion. While these inhibitors have shown dramatic results in some cancer patients, they only seem to work for a small percentage. As a result, research is shifting towards combining them with other cancer treatments, and exploring potential new inhibitors. These advances are expected to revolutionize cancer care.
North Korean Hackers Use Fake U.S. Companies to Spread Malware in Crypto Industry: Report
North Korean hackers reportedly set up shell companies in the US to penetrate the crypto sector and target developers via fake job offers, according to
